Please enable JavaScript in your browser. 
Skip to main content
Drug Information Portal National Library of Medicine
Home
 
       Home    Substance
     
Result
PropertyValue
Drug Name: Fenebrutinib [INN] View Structure
Description: MeSH: Inhibits Brutons tyrosine kinase

NCI: BTK inhibitor GDC-0853. An orally available inhibitor of Brutons tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival. (NCI Thesaurus) 



 
 
Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
Drug Information Portal Mobile Site
Last updated: Sep 2017
USA.gov